Clovis Oncology Inc. (CLVS) Fundamentals

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
SHARE INFORMATION
Market Cap$ 209,496,312
Shares Outstanding144,480,215
Float141,704,631
Percent Float98.08%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 148,757,000
Latest Fiscal EPS$ -2.30
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions309
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months10,305,049
Institutional Holdings Percent60.5%
Institutional Sold Previous 3 Months41,037,709
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months88,117
Insider Holdings Percent1.4
Insider Sold Previous 3 Months71,152
Insider Shares Owned2,002,729
TRADING INFO
52 Week High$ 5.00
52 Week Low$ 0.58
52 Week High Change$ -69.85
21 Day Moving Average$ 1.7348
21 Day Extended Moving Average$ 1.6669
50 Day Moving Average$ 1.6025
50 Day Extended Moving Average$ 1.6646
200 Day Moving Average$ 2.161
200 Day Extended Moving Average$ 2.3181
10 Day Average Volume4,290,405
20 Day Average Volume4,700,727
30 Day Average Volume12,832,221
50 Day Average Volume15,014,254
Alpha0.008292
Beta0.4275
Standard Deviation0.572048
R20.001397
7 Day Price Change$ -0.19
7 Day Percent Change-11.59%
21 Day Price Change$ -0.48
21 Day Percent Change-24.87%
30 Day Price Change$ -1.23
30 Day Percent Change-45.9%
Month to Date Price Change$ -0.22
Month to Date Percent Change-13.17%
Quarter to Date Price Change$ -0.35
Quarter to Date Percent Change-19.44%
180 Day Price Change$ -0.45
180 Day Percent Change-23.68%
200 Day Price Change$ -0.74
200 Day Percent Change-33.79%
Year to Date Price Change$ -1.26
Year to Date Percent Change-46.49%

Clovis Oncology Inc. (CLVS) Key Ratios

PROFITABILITY
EBIT Margin-163.9%
EBITDA Margin-158.3%
Pre-Tax Profit Margin-339.8%
Profit Margin Count0.0%
Gross Margin72.8%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 140,274,000
Revenue Per Share$ 0.9709
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book-0.50
Total Debt To Equity0.00
Int Coverage-6.80
Current Ratio1.20
Leverage Ratio-1.50
Quick Ratio1.00
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-0.80
Enterprise Value$ 799,194,135
Price to Sales1.4935
Price to Free Cash-1.20
PE High Last 5 Years-1.60
Price To Book0.00
Price To Cash Flow0.00
PE Low Last 5 Years-4.40
Price to Tangible Book-0.50
MANAGEMENT EFFECTIVENESS
Receivables Turnover5.40
Invoice Turnover2.20
Assets Turnover0.30
Return Assets-58.61
Return on Equity95.64
Return on Capital0.00

Clovis Oncology Inc. (CLVS) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOPatrick J. Mahaffy
Emplyoees413
Last AuditUQ
CIK0001466301
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address5500 Flatiron Parkway
Suite 100
Boulder, CO 80301
Websitehttps://www.clovisoncology.com
Facsimile+1 303 245-0360
Telephone+1 303 625-5000
Emailbburkart@clovisoncology.com


Your Recent History
NASDAQ
CLVS
Clovis Onc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.